Market Cap (In USD)
40.88 Million
Revenue (In USD)
-
Net Income (In USD)
-7.31 Million
Avg. Volume
95.91 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.63-3.23
- PE
- -
- EPS
- -
- Beta Value
- 0.238
- ISIN
- US2975841048
- CUSIP
- -
- CIK
- 1844417
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Cheng Liu Ph.D.
- Employee Count
- -
- Website
- https://www.estrellabio.com
- Ipo Date
- 2021-09-14
- Details
- Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
More Stocks
-
CNNCCannonau Corp.
CNNC
-
CBOX
-
600993
-
001230
-
SDZNYSandoz Group AG
SDZNY
-
DQJCY
-
000930
-
HEN